Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity
- 1 January 2005
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 101 (1-3), 93-109
- https://doi.org/10.1016/j.jconrel.2004.07.018
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- MMP‐2 sensitive, VEGF‐bearing bioactive hydrogels for promotion of vascular healingJournal of Biomedical Materials Research Part A, 2004
- Cell‐demanded release of VEGF from synthetic, biointeractive cell‐ingrowth matrices for vascularized tissue growthThe FASEB Journal, 2003
- Therapeutic stem and progenitor cell transplantation for organ vascularization and regenerationNature Medicine, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)Circulation, 2002
- Engineering of vascular ingrowth matrices: Are protein domains an alternative to peptides?The Anatomical Record, 2001
- Covalently conjugated VEGF–fibrin matrices for endothelializationJournal of Controlled Release, 2001
- Development of growth factor fusion proteins for cell‐triggered drug deliveryThe FASEB Journal, 2001
- Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibitionSurgery, 1996
- Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions*Surgery, 1995